Dômes Pharma Group acquires a stake in StemT Laboratory, specialist stem-cell therapy for veterinary applications

The Dômes Pharma group, a long-standing player in animal health, announces an equity investment in StemT, a French start-up specialising in the veterinary use of stem cells.

Founded and chaired since 2015 by Thibault Lataillade, StemT is a French biotechnology laboratory specialising in veterinary cell therapy for horses, dogs and cats. StemT’s mission is to expand the use of veterinary stem cells and to offer innovative and accessible treatments for inflammatory, orthopaedic and immunologicaldiseases. The Laboratory has numerous scientific partnerships with French universities, in particular the ENV-Alfort and VetAgro Sup Veterinary Schools, INSERM and the University of Paris 13.

Like the Dômes Pharma Group, StemT is a family company that carries out all of its R&D and production in France. These common points have convinced Anne Chauder, President of the Group, to invest in this young company: “This decision confirms the Dômes Pharma Group’s desire to be involved in the research of innovative therapies for the fields in which our subsidiary, the TVM Laboratory, has historically been innovative, such as ophthalmology or neurology. Stem cells open up countless therapeutic possibilities and hopes for curing previously incurable diseases. We are proud to support the research of the StemT teams and to be associated with the progress that will be made in the coming years.”

Stem cells: a promising therapy

Stem Cell Therapy, which consists of injecting stem cells into the patient to restore the activity of a tissue or organ, offers tremendous hope for pathologies with an inflammatory and degenerative component. For humans, the use of stem cells is the subject of many trial programs to treat various diseases such as Parkinson’s disease, DNLA, certain types of cancers, etc. Several hundred projects involving this type of therapy are underway around the world.

Animal health also has high hopes for cellular therapies. In the United States, several thousand dogs already benefit from cellular therapies in the treatment of osteoarthritis, a technique that has long been used for horses in the United Kingdom. There are also countless possible applications and StemT deploys therapies in other areas such as cat caudal stomatitis, which degrades the animal’s mouth and can lead to euthanasia or the treatment of chronic inflammatory disease of the dog’s intestine – the equivalent of Crohn’s disease.

 

Comments are closed.